BRPI1012560A2 - anticorpos anti-fcrh5 e imunoconjugados e métodos de uso - Google Patents
anticorpos anti-fcrh5 e imunoconjugados e métodos de usoInfo
- Publication number
- BRPI1012560A2 BRPI1012560A2 BRPI1012560A BRPI1012560A BRPI1012560A2 BR PI1012560 A2 BRPI1012560 A2 BR PI1012560A2 BR PI1012560 A BRPI1012560 A BR PI1012560A BR PI1012560 A BRPI1012560 A BR PI1012560A BR PI1012560 A2 BRPI1012560 A2 BR PI1012560A2
- Authority
- BR
- Brazil
- Prior art keywords
- fcrh5
- methods
- immunoconjugate antibodies
- immunoconjugate
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21175409P | 2009-04-01 | 2009-04-01 | |
| US16621409P | 2009-04-02 | 2009-04-02 | |
| PCT/US2010/029521 WO2010114940A1 (en) | 2009-04-01 | 2010-03-31 | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012560A2 true BRPI1012560A2 (pt) | 2016-07-26 |
Family
ID=42236394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012560A BRPI1012560A2 (pt) | 2009-04-01 | 2010-03-31 | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8362213B2 (https=) |
| EP (1) | EP2414395A1 (https=) |
| JP (2) | JP6099976B2 (https=) |
| KR (1) | KR20120003478A (https=) |
| CN (1) | CN102369218B (https=) |
| AR (1) | AR076030A1 (https=) |
| AU (1) | AU2010232682A1 (https=) |
| BR (1) | BRPI1012560A2 (https=) |
| CA (1) | CA2756988A1 (https=) |
| CL (1) | CL2011002418A1 (https=) |
| IL (1) | IL215404A0 (https=) |
| MX (1) | MX2011010265A (https=) |
| PE (1) | PE20120877A1 (https=) |
| RU (2) | RU2583270C2 (https=) |
| SG (1) | SG174930A1 (https=) |
| TW (1) | TW201039846A (https=) |
| WO (1) | WO2010114940A1 (https=) |
| ZA (1) | ZA201107128B (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2583270C2 (ru) | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| RU2587621C2 (ru) | 2009-04-01 | 2016-06-20 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US8962804B2 (en) * | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| EP2953976B1 (en) * | 2013-02-08 | 2021-03-24 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| WO2014157704A1 (ja) * | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン |
| SG11201507883SA (en) | 2013-03-29 | 2015-10-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1-antigen peptide conjugate vaccine |
| US10071170B2 (en) | 2013-06-24 | 2018-09-11 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
| TWI725931B (zh) * | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| ES2754397T3 (es) | 2013-10-11 | 2020-04-17 | Asana Biosciences Llc | Conjugados de proteína-polímero-fármaco |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| AU2015339012B2 (en) | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| AU2015357543B2 (en) | 2014-12-05 | 2021-10-21 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof |
| CN108064246A (zh) * | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| DK3310814T5 (da) | 2015-06-16 | 2024-10-07 | Hoffmann La Roche | Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse |
| US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| BR112018011336A2 (pt) * | 2015-12-04 | 2018-12-04 | Memorial Sloan-Kettering Cancer Center | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer |
| JPWO2017188346A1 (ja) * | 2016-04-27 | 2019-02-28 | 国立大学法人 東京大学 | マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法 |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| US12383608B2 (en) | 2016-11-30 | 2025-08-12 | Sumitomo Pharma Co., Ltd. | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| WO2019020745A1 (en) | 2017-07-28 | 2019-01-31 | F. Hoffmann-La Roche Ag | Bispecific antibody formulation |
| EP4321523A3 (en) | 2017-08-10 | 2024-04-24 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivatives and antibody-drug conjugates including same |
| PL3666787T3 (pl) * | 2017-08-10 | 2024-04-29 | Sumitomo Pharma Co., Ltd. | Koniugaty przeciwciało-lek zawierające pochodną hemiasterliny |
| US10766613B2 (en) * | 2017-11-28 | 2020-09-08 | Textron Innovations Inc. | System and method for rotorcraft-weight-on-wheels flight state transition control |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| IL325995A (en) | 2018-02-08 | 2026-03-01 | Genentech Inc | Bispecific antigen binding molecules and methods of use |
| US12180301B2 (en) | 2018-03-06 | 2024-12-31 | Imcare Biotech, Llc | Serine protease inhibitor kazal (SPIK) compositions and methods |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US12247245B2 (en) | 2018-07-25 | 2025-03-11 | Northeastern University | Selectivity screening for antimicrobial compounds |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| JP7432531B2 (ja) | 2019-02-13 | 2024-02-16 | 住友ファーマ株式会社 | システイン残基を有するヘミアスタリン誘導体 |
| JP7560255B2 (ja) * | 2019-02-13 | 2024-10-02 | 住友ファーマ株式会社 | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 |
| WO2020166592A1 (ja) * | 2019-02-13 | 2020-08-20 | 大日本住友製薬株式会社 | ヘミアスタリン誘導体とその抗体薬物複合体 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| US12377162B2 (en) | 2019-07-08 | 2025-08-05 | Imcare Biotech, Llc | Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use |
| EP4028132A1 (en) | 2019-09-11 | 2022-07-20 | Imcare Biotech, LLC | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| CN115023441A (zh) | 2019-12-18 | 2022-09-06 | 特诺福尔股份有限公司 | 与cd38结合的重链抗体 |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| CN116368154A (zh) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
| WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
| US20260070986A1 (en) | 2021-11-03 | 2026-03-12 | Affimed Gmbh | Bispecific cd16a binders |
| WO2023201299A1 (en) * | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
| US11958906B2 (en) | 2022-04-13 | 2024-04-16 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| CN116199772B (zh) * | 2022-11-16 | 2023-10-17 | 怡道生物科技(苏州)有限公司 | Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用 |
| TW202544034A (zh) | 2024-05-06 | 2025-11-16 | 美商榮都醫療公司 | 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體 |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
| US20030068623A1 (en) | 1997-06-16 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| AU2048901A (en) * | 1999-11-29 | 2001-06-04 | Trustees Of Columbia University In The City Of New York, The | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| US7105149B1 (en) | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
| US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| CA2450793A1 (en) * | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| DE60238143D1 (de) | 2001-09-18 | 2010-12-09 | Genentech Inc | Zusammensetzungen und verfahren für die diagnose von tumoren |
| US7888478B2 (en) | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7858330B2 (en) | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| EP1696963A2 (en) | 2003-12-24 | 2006-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| NZ579482A (en) * | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| DK1791565T3 (en) * | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| WO2006039238A2 (en) | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| KR20070115881A (ko) * | 2005-01-12 | 2007-12-06 | 메다렉스, 인코포레이티드 | 아이아르티에이-2 항체 및 그의 용도 |
| PL2135881T3 (pl) * | 2005-06-20 | 2012-02-29 | Genentech Inc | Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu |
| WO2008109533A2 (en) * | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
| RU2587621C2 (ru) | 2009-04-01 | 2016-06-20 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| RU2583270C2 (ru) | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
-
2010
- 2010-03-31 RU RU2011144119/10A patent/RU2583270C2/ru not_active IP Right Cessation
- 2010-03-31 CN CN201080014347.1A patent/CN102369218B/zh not_active Expired - Fee Related
- 2010-03-31 KR KR1020117025849A patent/KR20120003478A/ko not_active Abandoned
- 2010-03-31 BR BRPI1012560A patent/BRPI1012560A2/pt not_active IP Right Cessation
- 2010-03-31 SG SG2011069895A patent/SG174930A1/en unknown
- 2010-03-31 MX MX2011010265A patent/MX2011010265A/es active IP Right Grant
- 2010-03-31 WO PCT/US2010/029521 patent/WO2010114940A1/en not_active Ceased
- 2010-03-31 TW TW099109950A patent/TW201039846A/zh unknown
- 2010-03-31 US US12/751,791 patent/US8362213B2/en not_active Expired - Fee Related
- 2010-03-31 PE PE2011001751A patent/PE20120877A1/es not_active Application Discontinuation
- 2010-03-31 CA CA2756988A patent/CA2756988A1/en not_active Abandoned
- 2010-03-31 AU AU2010232682A patent/AU2010232682A1/en not_active Abandoned
- 2010-03-31 RU RU2016110891A patent/RU2016110891A/ru not_active Application Discontinuation
- 2010-03-31 JP JP2012503682A patent/JP6099976B2/ja not_active Expired - Fee Related
- 2010-03-31 EP EP10711526A patent/EP2414395A1/en not_active Ceased
- 2010-03-31 AR ARP100101080A patent/AR076030A1/es not_active Application Discontinuation
-
2011
- 2011-09-27 IL IL215404A patent/IL215404A0/en unknown
- 2011-09-29 ZA ZA2011/07128A patent/ZA201107128B/en unknown
- 2011-09-30 CL CL2011002418A patent/CL2011002418A1/es unknown
-
2012
- 2012-11-09 US US13/673,565 patent/US9017951B2/en not_active Expired - Fee Related
-
2015
- 2015-08-27 JP JP2015168182A patent/JP2016028052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG174930A1 (en) | 2011-11-28 |
| RU2583270C2 (ru) | 2016-05-10 |
| JP2012522513A (ja) | 2012-09-27 |
| CA2756988A1 (en) | 2010-10-07 |
| HK1166805A1 (en) | 2012-11-09 |
| WO2010114940A1 (en) | 2010-10-07 |
| US8362213B2 (en) | 2013-01-29 |
| US20110171125A1 (en) | 2011-07-14 |
| IL215404A0 (en) | 2011-12-29 |
| KR20120003478A (ko) | 2012-01-10 |
| AR076030A1 (es) | 2011-05-11 |
| US9017951B2 (en) | 2015-04-28 |
| JP2016028052A (ja) | 2016-02-25 |
| CN102369218A (zh) | 2012-03-07 |
| AU2010232682A1 (en) | 2011-11-10 |
| EP2414395A1 (en) | 2012-02-08 |
| RU2016110891A (ru) | 2018-11-27 |
| CN102369218B (zh) | 2014-07-16 |
| CL2011002418A1 (es) | 2012-03-16 |
| JP6099976B2 (ja) | 2017-03-29 |
| TW201039846A (en) | 2010-11-16 |
| ZA201107128B (en) | 2012-12-27 |
| PE20120877A1 (es) | 2012-08-06 |
| US20130089497A1 (en) | 2013-04-11 |
| MX2011010265A (es) | 2011-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012676A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| BRPI1012560A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| PT2247620T (pt) | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização | |
| PT2474557E (pt) | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização | |
| BRPI1014544A8 (pt) | anticorpos anti-il-17f e metodos de uso dos mesmos | |
| PL2990421T3 (pl) | Przeciwciała anty-ceacam1 oraz sposoby ich stosowania | |
| BRPI0813514A2 (pt) | anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso | |
| BR112014028366A2 (pt) | anticorpos anti-ly6e e imunoconjugados e métodos de uso | |
| PL2427212T3 (pl) | Przeciwciała anty cd-100 i sposoby ich zastosowania | |
| BRPI1011384A2 (pt) | pro-proteinas e seus metodos de uso | |
| BR112012018329A2 (pt) | agentes de coloração e métodos de uso destes | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| PL2488551T3 (pl) | Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania | |
| BRPI1007175A2 (pt) | Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso | |
| PL2644194T3 (pl) | Kombinacje koniugatu przeciwciała anty-HER2-lek i docetakselu | |
| BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
| BRPI0821110A2 (pt) | Anticorpo anti nr-10 e uso do mesmo | |
| BRPI0922708A2 (pt) | peptídeos mini-hepcidina e métodos de uso do mesmo | |
| BR112013014321A2 (pt) | moduladores inovadores e métodos de uso | |
| BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
| CO7020870A2 (es) | Anticuerpos anti-htra1 y métodos de uso | |
| BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
| BRPI1005670A2 (pt) | composições adjuvantes e métodos de uso | |
| CR20130133A (es) | Composiciones de anticuerpo y mètodos de uso | |
| BR112014010774A2 (pt) | anticorpos anti-kdr e métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |